Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling.

@article{Meuwis2007BiomarkerDF,
  title={Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling.},
  author={M. Meuwis and M. Fillet and P. Geurts and D. De seny and L. Lutteri and J. Chapelle and V. Bours and L. Wehenkel and J. Belaiche and M. Malaise and E. Louis and M. Merville},
  journal={Biochemical pharmacology},
  year={2007},
  volume={73 9},
  pages={
          1422-33
        }
}
Crohn's disease and ulcerative colitis known as inflammatory bowel diseases (IBD) are chronic immuno-inflammatory pathologies of the gastrointestinal tract. These diseases are multifactorial, polygenic and of unknown etiology. Clinical presentation is non-specific and diagnosis is based on clinical, endoscopic, radiological and histological criteria. Novel markers are needed to improve early diagnosis and classification of these pathologies. We performed a study with 120 serum samples collected… Expand
Integrated serum proteins and fatty acids analysis for putative biomarker discovery in inflammatory bowel disease.
TLDR
The biological functions and pathways involved in the various subsets of IBD, including Crohn's disease and ulcerative colitis, were identified and coagulation, fibrinolysis and acute phase response processes were found to be strongly involvement in the condition. Expand
New proteomic approaches for biomarker discovery in inflammatory bowel disease
TLDR
The current understanding in IBD biomarkers is analyzed and report the current understanding and potential future biomarkers and new developments of proteomics, such as subproteomics, are discussed as an innovative approach for the classification of patients according to their pattern of protein expression. Expand
Update on current applications of proteomic in the study of inflammatory bowel disease
TLDR
This review analyzes and reports the current knowledge in proteomic application and strategies in the study of inflammatory bowel disease and reports on the lack of a panel of biomarkers among a significant number of patients in large clinical trials. Expand
Serum Protein Profiling of Adults and Children With Crohn Disease
TLDR
Interestingly, a differential expression of several proteins in adults versus paediatric patients with CD is found, indicating that the expression of these proteins may be implicated in the onset or progression of CD in these 2 subgroups of patients. Expand
Serum Biomarkers for Inflammatory Bowel Disease
TLDR
Serum profiling and non-coding RNAs are just starting to blossom but reveal great promise for future clinical practice, and combining different biomarkers can be valuable in improving performance of disease evaluation. Expand
New biomarkers of Crohn’s disease: serum biomarkers and development of diagnostic tools
TLDR
Diagnosis tests based on the detection/quantification of specific acute-phase reactant proteins, enzymes and derived antibody response developed by inflammatory bowel disease patients for pathogens or symbiotic flora determinant, as well as autoantibodies are described. Expand
Subphenotypes of inflammatory bowel disease are characterized by specific serum protein profiles
TLDR
The novel PEA method and a panel of inflammatory proteins are used to characterize the inflammatory serum protein profiles of Crohn’s disease and ulcerative colitis, using the novel proximity extension assay, and identify proteins with significantly different quantities in CD patients and UC patients compared to HCs. Expand
Laboratory markers in ulcerative colitis: Current insights and future advances.
TLDR
The ability to determine the type, severity, prognosis and response to therapy of UC, using biomarkers has long been a goal of clinical researchers and the addition of new serological markers will add significant benefit. Expand
Metabolomic profiling in inflammatory bowel disease
TLDR
Serum Metabolomic profiling may represent a novel technology which could be used to distinguish individuals with CD from those with UC and healthy controls, and should be considered for use in clinical practice. Expand
Biomarkers in inflammatory bowel disease: current practices and recent advances.
  • H. Iskandar, M. Ciorba
  • Biology, Medicine
  • Translational research : the journal of laboratory and clinical medicine
  • 2012
TLDR
The discovery of novel biomarkers, which can correlate with mucosal healing or predict long-term disease course has the potential to significantly improve patient care and highlights recent advances in IBD biomarker discovery. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 67 REFERENCES
Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease.
TLDR
Fecal calprotectin predicts clinical relapse of disease activity in patients with Crohn's disease and UC, whereas small intestinal permeability is a useful predictor of relapse in Patients with small intestinal CD. Expand
[Serum acute phase proteins for determining disease activity of ulcerative colitis and Crohn disease].
We studied the activity assessment of ulcerative colitis and Crohn's disease by 5 acute phase reactants: C-reactive protein (CRP), alpha 1-acid glycoprotein, alpha 1 antitrypsin, haptoglobin andExpand
Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease.
TLDR
Fecal calprotectin, intestinal permeability, and positive Rome I criteria provide a safe and noninvasive means of helping differentiate between patients with organic and nonorganic intestinal disease. Expand
Laboratory markers in IBD: useful, magic, or unnecessary toys?
TLDR
Until more data become available, the use of CRP and other laboratory markers should be seen as an additive tool to clinical observation and physical examination rather than a replacement. Expand
Proteomic patterns: their potential for disease diagnosis
TLDR
This review will discuss the basics of SELDI protein chip technology and highlight its recent applications in disease biomarker discovery with emphasis on cancer diagnosis. Expand
Non-invasive investigation of inflammatory bowel disease.
TLDR
It is now clear that single stool assay of neutrophil specific proteins (calprotectin, lactoferrin) give the same quantitative data on intestinal inflammation as the 4 day faecal excretion of 111Indium labelled white cells, and Faecal calprotectin is shown to be increased in over 95% of patients with IBD and correlates with clinical disease activity. Expand
Discovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry ProteinChip approach.
TLDR
SELDI-TOF-MS technology allows rapid analysis of many serum samples, and use of decision tree boosting analysis as the main statistical method allowed us to propose a pattern of protein peaks specific for RA. Expand
Correlation of C‐Reactive Protein With Clinical, Endoscopic, Histologic, and Radiographic Activity in Inflammatory Bowel Disease
TLDR
CRP elevation in IBD patients is associated with clinical disease activity, endoscopic inflammation, severely active histologic inflammation (in CD patients), and several other biomarkers of inflammation, but not with radiographic activity. Expand
Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease.
TLDR
A large range in sensitivities and specificities of ASCA for CD is seen with different ASCA assays, mainly as a consequence of the cutoff value chosen for each individual assay. Expand
C-Reactive Protein as a Marker for Inflammatory Bowel Disease
TLDR
An increased CRP (>45 mg/L) in patients with IBD predicts with a high certainty the need for colectomy and this by reflecting severe ongoing and uncontrollable inflammation in the gut. Expand
...
1
2
3
4
5
...